ClinicalTrials.gov
public full text
Public Domain
Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors
This is a Phase II study to evaluate the activity of brentuximab vedotin in relapsed/refractory non-seminomatous germ cell tumors (NSGCT).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors#969167
- A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma#184856
- A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma#238097
- Effectiveness and safety of brentuximab vedotin-containing regimen versus standard chemotherapy in relapsed or refractory Hodgkin lymphoma: a multicenter cohort study.#362560
- Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas#838409
Record · ID 1484170
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive